Bio-Techne Corp (FRA:TE1)
€ 76.5 1 (1.32%) Market Cap: 11.96 Bil Enterprise Value: 12.28 Bil PE Ratio: 65.48 PB Ratio: 6.45 GF Score: 92/100

Bio-Techne Corp at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 01:30PM GMT
Release Date Price: €40 (-5.33%)
Jack Meehan
Barclays Bank PLC, Research Division - VP & Senior Research Analyst

Hi. This is Jack Meehan with the Barclays Life Science Tools and Diagnostics team. Thank you for joining us this morning for the Barclays Virtual Health Care Conference. Pleased to be joined with -- now with Bio-Techne CEO, Chuck Kummeth as well as Head of Investor Relations, Dave Clair. Chuck, would you like to kick it off with any introductory comments?

Charles R. Kummeth
Bio-Techne Corporation - CEO, President & Director

Yes, thanks. I'll give a minute or 2 on just accompanying some background. So I've been here 7 years; most of my team, 5 or 6; brought in from places like Thermo Fisher and the places I've worked and as well as other areas like LifeTech, some strong team. Most of the people running our businesses have run billion-dollar things or bigger. So a great team going there.

We've done 15 acquisitions in the last 6 years, and we've grown from roughly about a $300 million revenue rate. When I started to -- we were 7 -- $14 million last fiscal year; June

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot